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Abstract
Background: Population heterogeneity may be a significant confounding factor hampering detection and verification of
late onset Alzheimer's disease (LOAD) susceptibility genes. The Amish communities located in Indiana and Ohio are
relatively isolated populations that may have increased power to detect disease susceptibility genes.
Methods: We recently performed a genome scan of dementia in this population that detected several potential loci.
However, analyses of these data are complicated by the highly consanguineous nature of these Amish pedigrees.
Therefore we applied the Combinatorial Mismatch Scanning (CMS) method that compares identity by state (IBS) (under
the presumption of identity by descent (IBD)) sharing in distantly related individuals from such populations where
standard linkage and association analyses are difficult to implement. CMS compares allele sharing between individuals in
affected and unaffected groups from founder populations. Comparisons between cases and controls were done using
two Fisher's exact tests, one testing for excess in IBS allele frequency and the other testing for excess in IBS genotype
frequency for 407 microsatellite markers.
Results: In all, 13 dementia cases and 14 normal controls were identified who were not related at least through the
grandparental generation. The examination of allele frequencies identified 24 markers (6%) nominally (p ≤ 0.05)
associated with dementia; the most interesting (empiric p ≤ 0.005) markers were D3S1262, D5S211, and D19S1165. The
examination of genotype frequencies identified 21 markers (5%) nominally (p ≤ 0.05) associated with dementia; the most
significant markers were both located on chromosome 5 (D5S1480 and D5S211). Notably, one of these markers
(D5S211) demonstrated differences (empiric p ≤ 0.005) under both tests.
Conclusion: Our results provide the initial groundwork for identifying genes involved in late-onset Alzheimer's disease
within the Amish community. Genes identified within this isolated population will likely play a role in a subset of late-
onset AD cases across more general populations. Regions highlighted by markers demonstrating suggestive allelic and/
or genotypic differences will be the focus of more detailed examination to characterize their involvement in dementia.
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Background
With over 4 million individuals affected with Alzheimer's
disease (AD) in the U.S., dementia of the Alzheimer's
Type (DAT) is the leading cause of dementia in the elderly.
These current estimates are projected to triple over the
next 50 years as the population ages [1-3]. AD has a com-
plex etiology with strong genetic and environmental
determinants. Tremendous evidence suggests the involve-
ment of at least three genes in early-onset autosomal dom-
inant AD. Amyloid precursor protein (APP on
chromosome 21) [4,5], presenilin I (PSEN1 on chromo-
some 14) [6-9], and presenilin II (PSEN2 on chromosome
1) [10,11] are all prominent early-onset Alzheimer's dis-
ease genes. Understanding of the more common late-
onset Alzheimer disease (LOAD), is centered on the role
of one universally accepted risk gene, the apolipoprotein
E locus (APOE) [12]. The APOE  ε4 allele (frequency
approximately 16%) [13,14] acts in a dose-related man-
ner to increase risk for LOAD and decrease age-of-onset
[15,16]. Although its involvement is without question,
APOE accounts for less than half of late-onset AD suscep-
tibility [15]. Given the strong heritability of AD, other
genetic factors are likely to be involved. Multiple linkage
screens have been conducted to elucidate additional
regions harboring susceptibility genes for late-onset AD
[17-35]. While regions on chromosomes 9, 10 and 12 are
most consistently identified, candidate genes within those
regions have yet to be clearly implicated in AD. Mean-
while, numerous other regions have been implicated but
have not been the focus of detailed study due to the prom-
inence of 9, 10, and 12.
Though numerous promising LOAD candidate genes have
been examined, the lack of replication across studies has
made a definitive declaration of their involvement diffi-
cult (Reviewed in [36,37]). Genetic heterogeneity is likely
to be one of the underlying reasons for this lack of repli-
cation. Given this, one possible solution is to study popu-
lations likely to be more genetically homogeneous,
thereby enriching for a more homogeneous set of risk alle-
les. The North American Amish population is a relatively
isolated, genetically well-defined homogeneous popula-
tion, well-suited for this type of study. Further detail
regarding the establishment of the North American Amish
population has been described elsewhere [38-43]. While
there may be a number of LOAD susceptibility genes con-
tributing to disease in the general population, the rela-
tively homogeneous Amish population is likely to contain
a smaller set of risk alleles.
One challenge in performing linkage analysis in Amish
pedigrees is to utilize the extensive pedigree information
available while maintaining tractability of the computa-
tions. Due to their strong religious and cultural beliefs, the
Amish very rarely marry outside of their communities,
thereby promoting a genetically isolated population [38-
41]. This in turn has led to an elevated degree of consan-
guinity, yielding family pedigrees that contain many
loops that can often be traced back three or more genera-
tions. In fact, through use of the Anabaptist Genealogy
Database (AGDB), we find that 93% of our overall study
population of 460 individuals and more specifically 25/
27 (93%) of the individuals used in this study can be
traced back 10 generations to a single founding couple.
Moreover, 100% of individuals within our entire Amish
sample (460) belong to one very large extended pedigree
when allowing parent-child and marriage links to be
included [44]. Since LOAD cannot be ascertained until
late in life, affected individuals are usually only available
for genotyping in a single generation. Hence, by far, most
of the individuals in the pedigree have unknown pheno-
type and genotype status. It should be noted that there are
limited methodologies available to analyze disease gene
linkage utilizing such large complex pedigrees. One such
method is SimWalk2 which utilizes descent graph theory
and Markov Chain Monte Carlo (MCMC) simulation to
compute lod scores [45]. This is a computationally
demanding process and because of the uncertainty of
MCMC convergence, the accuracy of the scores obtained
may be difficult to assess.
Combinatorial mismatch scanning (CMS) is an alterna-
tive technique to search for IBS sharing in distantly related
individuals from isolated founder populations where
standard linkage and association analyses are difficult to
implement. While several other methods could be imple-
mented, this approach was used because of its simplicity
in examining existing data. This method was also chosen
because at the onset of analysis, we lacked the more
detailed knowledge of the inter-relatedness of our sample
often required to perform similar, but more sophisticated
approaches within large inbred pedigrees [46-48]. This
strategy is designed to circumvent the confounding issue
of genetic heterogeneity, by examining affected and unaf-
fected persons from relatively small founder populations
[49]. By genetically evaluating case and control individu-
als selected from such a population, whose common
ancestor is no more closely related than grandparents,
some prevailing problems in allelic association studies of
complex disease within generally outbred populations
can be avoided. Population stratification can lead to
allelic association and be misinterpreted as linkage dise-
quilibrium. In this approach, population stratification is
less of an issue due to the relative isolation and common
heritage of the study population. Another difficulty facing
genetic studies within large outbred populations is that
these populations are likely to exhibit locus heterogeneity.
Within an isolated population, the probability that the
risk allele of interest might have entered the gene pool
only once or rarely, provides a great advantage. This inBMC Medical Genetics 2006, 7:19 http://www.biomedcentral.com/1471-2350/7/19
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turn will likely facilitate the distinction between true and
spurious association. Heath and colleagues highlight
another advantage of examining isolated populations by
alluding to the potential for detecting gene-gene interac-
tions [49]. These epistatic interactions may play a substan-
tial role in complex disease, effectively hampering the
ability to detect association using single locus methods
within heterogeneous populations. With reference to this
problem, there are good reasons to believe that epistatic
(gene-gene) interactions are ubiquitous in complex dis-
ease and may in fact be more important than single-gene
effects [50].
Methods
Subjects and phenotypes
The Amish often have large sibships and extensive pedi-
gree records that permit the accurate estimation of IBS
gene sharing to be accurately evaluated. The estimated
coefficient of inbreeding for the entire population is
0.0151, which is approximately equivalent to having sec-
ond cousins as parents [51]. This effect has led present-
day Amish to possess genes inherited identically from a
common ancestor at rates higher than observed in the
general population. By searching the Anabaptist Geneal-
ogy Database (AGDB) with the query software Ped-
Hunter, we have determined the level of relatedness of our
sample more precisely [44,52]. We calculated the average
kinship coefficient for our overall ascertained Amish sam-
ple to be 0.019 ± 0.00053 (mean ± SEM). This measure
demonstrates a significant difference from the average
kinship coefficients calculated for the within cases group
(0.011 ± 0.0013, mean ± SEM), the within controls group
(0.0094 ± 0.0011, mean ± SEM), and the between cases
and controls group (0.010 ± 0.00065, mean ± SEM).
These calculations provide us with additional confidence
that our cases and controls are more distantly related to
each other relative to our overall sample population.
The subjects included in this study are a subset of individ-
uals described in extensive detail elsewhere [43]. Briefly,
individuals enrolled in the study each were assigned to
one of three clinical impression categories; dementia
(probable or possible Alzheimer's disease); unclear
(includes mild cognitive impairment (MCI)); or unaf-
fected (cognitively normal). Participants were adminis-
tered the Mini-Mental State Exam (MMSE) [53], with
possible scores ranging from 0 to 30. All individuals scor-
ing 27 or greater were classified as cognitively normal/
unaffected. Those scoring 23 or less were classified as cog-
nitively impaired and labeled as probable dementia.
Those who scored 24–26 had additional neuropsycholog-
ical testing including the Dementia Rating Scale (DRS)
[54], the Boston Naming Test (BNT) [55], and a reading
subtest from the Wide Range Achievement Test-Revised
(WRAT-R) [56]. Persons were categorized as having mild
cognitive impairment if their DRS score fell below an age-
adjusted threshold. Each case was discussed and a consen-
sus "final" diagnosis was determined using all available
information. For analytical purposes, the cases were clas-
sified as affected (demented), unclear (includes MCI), and
unaffected (cognitively normal).
Five Amish pedigrees were included in this study. Three
families were from Elkhart and LaGrange counties in Indi-
ana, one extended family from Adams county Indiana,
and one extended family from Holmes county Ohio. The
extended pedigree from Adams county has been the sub-
ject of other previous and ongoing studies of dementia in
the Amish [16,57]. Among the 115 individuals who were
genotyped, 40 were classified as having dementia, 9 were
classified as unclear, and 66 individuals were unaffected.
To minimize chance IBS inheritance, individuals selected
for the CMS analysis were unrelated through the grandpa-
rental generation [49]. For this current study we identified
13 dementia cases and 14 cognitively normal individuals
who met this requirement. This study was undertaken
after Institutional Review Board review and approval.
Molecular analysis
Following informed consent, blood samples were col-
lected from each individual and genomic DNA was
extracted from blood using standard procedures. Cell
lines have been initiated on most sampled individuals. All
DNA samples were coded and stored at 4°C until used.
Markers were genotyped at both the Vanderbilt and Duke
laboratories for all DNA samples. Laboratory personnel
were blinded to pedigree structure, affection status, and
location of quality control samples. Duplicate quality
control samples were placed both within and across plates
and equivalent genotypes were required for all quality
control samples to ensure accurate genotyping. At the
Vanderbilt laboratory, marker primer sequences were
obtained from the Genome Database [58] or designed
with Primer3 software [59] and synthesized by Invitrogen
Life Technologies (Carlsbad, CA). Amplification was per-
formed in a PCR Express machine (ThermoHybaid, Need-
ham Heights, MA) with the following conditions: 94°C-4
min.; 94°C-15 sec., AT-30 sec., 72°C-45 sec. (35 cycles);
72°C-4 min. PCR products were denatured for 3 min. at
95°C and run on a 6% polyacrylamide gel (Sequagel-
6®from National Diagnostics, Atlanta, GA) for ~1 hr. at 75
W. Gels were stained with a SybrGold®rinse (Molecular
Probes, Eugene, OR) and scanned with the Hitachi Biosys-
tems FMBIOII laser scanner (Brisbane, CA). Marker geno-
typing at the Duke laboratory was performed using
fluorescence imaging (Molecular Dynamics SI Fluorim-
ager) and a semi-automated allele calling system [60].BMC Medical Genetics 2006, 7:19 http://www.biomedcentral.com/1471-2350/7/19
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Hardy-Weinberg equilibrium calculations were per-
formed for each marker and Mendelian inconsistencies
were identified using PedCheck in the overall dataset [61].
Suspect genotypes were re-read by a different technician
or re-run as necessary to reduce errors. All microsatellite
markers were required to have >90% of possible geno-
types to be included in the analysis.
Statistical analysis
Comparisons between case and control genotype data for
the 407 microsatellite markers were conducted using the
R software package to perform Fisher's exact tests in r × c
Contingency Tables [62-64]. Each marker was examined
for both allele and genotype differences between individ-
uals affected with dementia and those without dementia.
The first test was for IBS allele frequency inequality
between the two classes, and the second test was for IBS
genotype frequency inequality between the two classes.
Fisher's exact test computes the probability p that the pat-
tern of alleles observed in the sample would be obtained
if there were truly no difference between the allele fre-
quencies among affected and unaffected individuals.
While our current sample size is adequate to detect mod-
erate to major effects (odds ratio of >6 with 80% power),
it does not preclude our ability to detect smaller effects
given that these power calculations are based on the
assumptions of complete independence of samples and
random sampling of the population, neither of which is
true.
To empirically evaluate the statistical significance of the
p-values computed in the CMS study, we permuted our
dataset. We randomly re-assigned affection status for
each of the 27 individuals maintaining the original total
of 13 cases and 14 controls. We then executed the
Fisher's exact test using the same allele and genotype data
in the original dataset for each of the 407 markers. The
distribution of p-values obtained from Fisher's exact test-
ing on 1000 randomized sets of data was then created for
both the allele and genotype comparisons to assess the
empiric thresholds. We would expect the Fisher's exact p-
value to match the p-value within the large distribution.
These permutations were needed to correct for any resid-
ual bias from unrecognized kinship correlation present.
Results
We tested 407 microsatellite markers for differences in
both allele frequency and genotype frequency between
Amish dementia cases and controls. We considered all
pointwise p-values and have chosen to report only mark-
ers demonstrating Fisher's exact p-values < 0.05 for either
allele or genotype frequency differences. This arbitrary
threshold was chosen to limit the results to be displayed
and to provide a reference point for discussion of markers
demonstrating nominally significant (albeit within the
null expectation given the number of markers examined)
evidence of association to dementia within our popula-
tion.
As an example, Table 1a shows the allele count data for
marker D5S211. There are eight D5S211 alleles in the
sample with 27 subjects being typed for 54 alleles. In the
example, the probability of this data being obtained if
there were no underlying difference between the allele dis-
tributions for the two classes is < 0.005 (Table 2). Table 1b
shows the genotype data for marker D5S211. Note that
out of the thirteen genotypes observed in the data only
one genotype is present in both affected and unaffected
classes. The probability of the data being obtained if there
were no underlying difference between the genotype dis-
tributions for the case and controls is < 0.005 (Table 2).
Markers demonstrating nominally significant (p ≤ 0.05)
differences between cases and controls are listed in Table
Table 1: Comparison of Allele and Genotype frequencies for 
D5S211 in dementia cases and controls
Allele counts
Alleles Cases Controls Totals
1 8 6 202
192 4 8 12
1 9 6 246
1 9 8 112
200 16 4 20
2 0 6 112
2 0 2 066
2 0 4 044
Totals 26 28 54
Genotype 
counts
Genotypes Cases Controls Totals
186/200 2 0 2
192/192 0 3 3
192/196 0 1 1
192/200 4 0 4
192/206 0 1 1
196/198 0 1 1
196/200 2 1 3
196/202 0 1 1
198/206 1 0 1
200/200 4 0 4
200/202 0 3 3
200/204 0 2 2
204/204 0 1 1
Totals 13 14 27
Bold highlights allele demonstrating greatest differenceBMC Medical Genetics 2006, 7:19 http://www.biomedcentral.com/1471-2350/7/19
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2. There were 24 out of 407 markers (6%) demonstrating
significant differences in allele frequency. The most signif-
icant markers were D3S1262, D5S211, and D19S1165.
When examining the markers for genotype frequency dif-
ferences, 21 out of 407 markers (5%) were significantly
different between our dementia cases and controls. The
most significant markers were D5S1480 and D5S211.
While there were seven markers (D3S1262, D4S1625,
D5S211, D6S1031, D8S1477, D8S272, D17S921, and
D18S481) with p-values ≤ 0.05 for both the allelic and
genotypic tests, only one marker (D5S211) was significant
at the empiric p ≤ 0.005 level for both tests. Although all
findings are uncorrected and there are no findings with
genome-wide significance, markers in close proximity to
those regions previously identified are of particular inter-
est for future study.
Discussion
We have detected a few microsatellite markers of particu-
lar interest, which demonstrate significant differences
between dementia cases and controls within our Amish
founder population using the combinatorial mismatch
scanning approach. The CMS concept is based on excess
IBS allele/genotype sharing between individuals sharing a
distant set of common founders [49]. The most notewor-
thy finding is on chromosome 5q35.2 at approximately
183 cM where we find evidence for both allele and geno-
type differences between our dementia cases and controls
for marker D5S211. In their large genome-wide linkage
study of Alzheimer's disease, Blacker et al. detected a
multipoint lod score of 1.3 at this same marker [32]. In a
recent study of consanguineous Israeli-Arab communities,
Farrer and colleagues found significant evidence for allele
frequency differences between AD cases and controls at
the closest marker (D5S400 at 175 cM) on chromosome 5
run in their study [33]. Positive findings across three dis-
tinct study populations suggest that a gene or genes within
this region of chromosome 5 may be involved in risk for
dementia of the Alzheimer's type (DAT). Thus future
examination of this region on chromosome 5 within our
Amish families is warranted. While another marker on
chromosome 5q31.3 (D5S1480 at 147 cM) demonstrated
genotype differences between dementia cases and con-
trols, this location is novel with respect to other previous
studies.
We also found evidence of allele frequency differences on
chromosome 3q27.3 at D3S1262 (201 cM). One study
tested for association with AD in a geographically distinct
Finnish population descended from a small group of orig-
inal founders [65]. This group found significant associa-
tion (empiric p = 0.007) at marker D3S1602 (also located
at 201 cM) within their AD sample. An interesting candi-
date gene at this location is SST, the gene encoding soma-
tostatin, which functions as a neurotransmitter in the
central nervous system. Somatostatin inhibits the release
of glucagon, growth hormone, gastrin, insulin, and secre-
tin. Additional evidence for this region stems from our
genome-wide linkage study within the Amish population,
for which we observed a suggestive two-point lod score of
2.42 at the nearby marker D3S2398 (209 cM) [43].
An additional marker demonstrating suggestive allele
frequency differences is located on chromosome
19p13.2 (D19S1165 at 36 cM). Hiltunen et al. had
detected evidence for association at two nearby markers
(D19S1034 and D19S433) spanning the region contain-
ing our significant results [65]. ICAM-1 (Intercellular
Adhesion Molecule 1), a previously-reported AD candi-
date gene, also lies within this region of interest. Pola et
al. showed that the ICAM-1 K469E gene polymorphism
was associated with AD in an Italian population [66].
This association was not, however, supported in studies
of the gene in Finnish and Spanish populations [67,68].
Additional strong evidence from previous work indicates
the presence of a late-onset AD locus within this region.
A study by Wijsman et al. provides substantial evidence
for a locus at approximately 35 cM affecting AD age at
onset [69]. While our study does not address age at onset,
it further suggests the involvement of this region in AD.
Another region of relative interest is on chromosome
4q31.2 at marker D4S1625. This marker located on chro-
mosome 4q at approximately 146 cM lies between two
markers (D4S2394 at 130 cM and D4S1548 at 154 cM)
demonstrating highly suggestive evidence for linkage
within our Amish population [43]. Further evidence for
this region stems from work by Pericak-Vance et al. where
they detect modest evidence for linkage to a marker only
4 cM away (D4S1629, lod = 1.32) from D4S1625 (Table
2) [26].
Given that our data may violate assumptions (i.e. normal-
ity and/or unrealized correlation) of the Fisher's exact test,
we determined the empiric p-value for our results through
permutation. We performed the Fisher's exact test on
1000 replicates containing the same original genotype
data, but with randomized affection status. The resulting
distribution of p-values was then used as an empiric meas-
ure of significance for our results (Table 2). On the whole,
the empiric p-value thresholds for our study showed the
Fisher's exact p-value to be somewhat more liberal than
expected.
We have previously performed a genome-wide linkage
screen for dementia within this population; however the
complex nature of the Amish pedigrees provides a chal-
lenge for linkage analysis, given the size and number of
consanguineous loops within these extended families.
Accordingly the linkage analysis by itself does not allowBMC Medical Genetics 2006, 7:19 http://www.biomedcentral.com/1471-2350/7/19
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Table 2: Microsatellite markers demonstrating nominally significant (p ≤ 0.05) empiric p-values for allele and genotype frequency 
differences between dementia cases and controls. Microsatellite markers in close proximity to those demonstrating significance in this 
study and found to be either linked (lod ≥ 1) or associated (p ≤ 0.05) in previous studies are also listed.
Chromosome Map Position 
(cM)
Mb Location Marker Fisher's Exact p-value Empiric p-value Max Lod 
Score
Study
Allele Genotype Allele Genotype
1 25 11.4 D1S2667 0.162 0.007 0.170 0.015
1 64 32.1 D1S396 0.043 0.449 0.050 0.407
2 38 17.4 D2S1360 0.028 0.243 0.035 0.228
2 74 50.7 D2S1352 0.200 0.026 0.208 0.032
2 252 237.9 D2S2968 0.688 0.018 0.684 0.025
3 119 103.7 D3S2459 0.223 0.007 0.231 0.014
3 153 140.7 D3S1764 0.029 0.271 0.035 0.248
3 177 168.7 D3S1763 1.69 Hahs et al.
3 201 187.5 D3S1602 0.007** Hiltunen et al.
32 0 1 1 8 7 . 7 D3S1262 0.001 0.019 0.003 0.026
3 209 191 D3S2398 2.16 Hahs et al.
3 216 193.8 D3S2418 1.18 Hahs et al.
4 78 D4S2367 0.557 0.015 0.557 0.022
4 130 130.7 D4S2394 2.12 Hahs et al.
41 4 6 1 4 3 . 9 D4S1625 0.032 0.013 0.038 0.020
4 154 152.5 D4S1548 3.01 Hahs et al.
4 158 158.7 D4S1629 1.32 Pericak-Vance 
et al. (2000)
5 8 D5S2849 0.590 0.031 0.589 0.038
5 92 82.3 D5S1347 0.060 0.002 0.068 0.007
5 98 89.2 D5S1725 1.47 Hahs et al.
51 4 7 1 4 4 . 1 D5S1480 0.465 0.001 0.467 0.005
5 175 168.4 D5S400 0.04* Farrer et al.
51 8 3 1 7 3 . 2 D5S211 0.001 0.001 0.002 0.004
5 183 173.2 D5S211 1.3 Blacker et al.
6 89 77.5 D6S1031 0.024 0.046 0.030 0.051
6 160 158 D6S1007 0.933 0.017 0.923 0.025
86 0 3 2 . 2 D8S1477 0.004 0.018 0.007 0.026
8 125 118.5 D8S592 0.387 0.032 0.391 0.038
81 5 4 1 3 7 . 8 D8S272 0.007 0.021 0.010 0.028
9 14 D9S2169 0.022 0.394 0.027 0.362
10 63 35.3 D10S1208 0.013 0.247 0.018 0.231
10 76 57.2 D10S1221 0.028 0.054 0.034 0.059
12 78 66.2 D12S1294 0.220 0.045 0.228 0.050
13 39 42.1 D13S325 0.027 0.070 0.033 0.072
13 76 96.7 D13S892 0.040 0.224 0.047 0.210
14 44 37.4 D14S306 0.020 0.104 0.026 0.103
14 94 86.3 D14S612 0.016 0.166 0.021 0.156
15 101 92.8 D15S816 0.046 0.158 0.053 0.150
15 116 98.9 D15S87 0.031 0.083 0.037 0.084
16 64 49.7 D16S3396 0.039 0.450 0.046 0.409
16 130 D16S2621 0.227 0.036 0.235 0.042
17 36 14.2 D17S921 0.024 0.026 0.030 0.032
17 126 77.8 D17S928 0.024 0.201 0.029 0.186
18 7 3.1 D18S481 0.017 0.006 0.022 0.013
18 109 D18S1362 0.431 0.021 0.434 0.028
19 21 6.1 D19S1034 0.013** Hiltunen et al.
19 33 9.7 D19S586 2.06 Hahs et al.
19 36 12.2 D19S1165 0.002 0.066 0.004 0.069
20 39 17.3 D20S470 0.027 0.206 0.033 0.191
21 27 30.6 D21S1270 0.245 0.010 0.253 0.018
Bold denotes markers nominally significant (p ≤ 0.05) in both allele and genotype comparisions
Italics highlights markers empirically significant at p ≤ 0.005
*SAS software was used to measure significant differences in allele frequency between DAT cases and controls
**Pearson's chi-square was calculated and then empirical significance was determined through examination of 1000 replicated datasets.BMC Medical Genetics 2006, 7:19 http://www.biomedcentral.com/1471-2350/7/19
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taking full advantage of the data available to us. To exam-
ine our data more thoroughly, we performed the combi-
natorial mismatch scan. Both this approach and the
linkage analysis utilize the high level of inter-relatedness,
within the Amish population, to their advantage. The
nature of the CMS analysis, allowed us to examine these
data without being computationally burdened by the size
or family structure of our population. These two methods
complement each other by allowing the examination of
the same data using both a family-based approach and a
"pseudo" case-control approach to identify regions across
the genome which are potentially involved in AD suscep-
tibility. We are fully aware of the limited power of our cur-
rent sample; however, these analyses should be viewed as
an adjunct to our recent genomic screen.
Conclusion
We have reported several markers across the genome
(chr3, 4, 5, and 19) to have significant allelic and/or gen-
otypic frequency differences between dementia cases and
controls within the combined Amish communities of
Ohio and Indiana. While the evidence presented here is
not overwhelming for any specific region, these results
must be viewed in conjunction with not only our genomic
screen but with findings across other studies within addi-
tional populations. In conclusion, our results provide the
groundwork for future detailed study of these regions
within our growing sample of Amish individuals.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
JLM directed and performed some of the analyses, col-
lated the results, and was responsible for preparing and
editing the manuscript and tables therein. DWH was
involved in the drafting of the manuscript and providing
input on the analyses. LJ was responsible for data manage-
ment and analysis. WKS provided input for the analysis,
helped in editing the manuscript, and provided financial
support through grant funding. KAW was key in all clini-
cal evaluations and provided input for the manuscript.
CEJ has been a longtime consultant for ascertainment and
recruitment from the Amish community due to his exten-
sive interaction within this isolated population. JMV coor-
dinated the genotyping of the microsatellite markers used
within this study. JLH and MPV are Principal Investigator
(PI) and co-PI, respectively. Both PIs were instrumental in
providing the infrastructure, aiding in the study design,
providing input in the manuscript, and supporting this
project as well as additional projects surrounding this
manuscript through their grant funding.
Acknowledgements
This work was funded through NIH/NIA grants AG19085, AG19757, 
AG19726, the Claude Pepper Center (AG11268), and a discovery grant 
from Vanderbilt University. Additional work was performed using the Van-
derbilt Center for Human Genetics Research Core facilities, the Vanderbilt 
General Clinical Research Center (M01 RR-00095), and the Duke Center 
for Human Genetics Core facilities. We thank all of the family participants 
and the Amish community members for so kindly agreeing to participate in 
our studies. Without their involvement, none of this research would have 
been possible.
References
1. Geldmacher DS, Whitehouse PJ Jr: Differential diagnosis of
Alzheimer's disease.  Neurology 1997, 48:S2-S9.
2. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's dis-
ease in the United States and the public health impact of
delaying disease onset.  Am J Public Health 1998, 88:1337-1342.
3. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer
disease in the US population: prevalence estimates using the
2000 census.  Arch Neurol 2003, 60:1119-1122.
4. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Watkins PC,
Myers RH, Feldman RG, Pollen D, Drachman D: The genetic defect
causing familial Alzheimer's disease maps on chromosome
21.  Science 1987, 235:885-890.
5. Goate AM, Chartier-Harlin MC, Mullan MC, Brown J, Crawford F,
Fidani L, Guiffra L, Haynes A, Irving N, James L, Mant R, Newton P,
Rooke K, Roques P, Talbot C, Pericak-Vance MA, Roses AD, William-
son R, Rossor M, Owen M, Hardy J: Segregation of a missense
mutation in the amyloid precursor protein gene with familial
Alzheimer's disease.  Nature 1991, 33:53-56.
6. St George-Hyslop P, Haines JL, Rogaev E, Mortilla M, Vaula G, Peri-
cak-Vance MA, Foncin J-F, Montesi M, Bruni A, Sorbi S, Rainero I,
Pinessi L, Pollen D, Polinsky R, Nee L, Kennedy J, Macciardi F, Rogaeva
E, Liang Y, Alexandrova N, Lukiw W, Schlumpf K, Tanzi R, Tsuda T,
Farrer L, Cantu J-M, Duara R, Amaducci L, Bergamini L, Gusella J,
Roses A, McLachlan DC: Genetic evidence for a novel familial
Alznheimer's disease locus on chromosome 14.  Nature Genet-
ics 1992, 2:330-334.
7. Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L,
Nemens E, White JA, Bonnycastle L, Weber JL, Alonso ME: Genetic
linkage evidence for a familial Alzheimer's disease locus on
chromosome 14.  Science 1992, 258:668-671.
8. Van Broeckhoven C, Backhovens H, Cruts M, De Winter G, Bruyland
M, Cras P, Martin JJ: Mapping of a gene predisposing to early-
onset Alzheimer's disease to chromosome 14q24.3.  Nat
Genet 1992, 2:335-339.
9. Sherrington R, Rogaev E, Liang Y, Rogaeva EA, Levesque G, Ikeda M,
Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin J-F, Bruni AC,
Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen
D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, DaSilva HAR, Haines
JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM,
St George-Hyslop PH: Cloning of a gene bearing missense
mutations in early-onset familial Alzheimer's disease.  Nature
1995, 375:754-760.
10. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell
WH, Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley AC, Fu Y-H,
Guenette SY, Galas D, Nemens E, Wijsman EM, Bird TD, Schellen-
berg GD, Tanzi RE: Candidate gene for the chromosome 1
familial Alzheimer's disease locus.  Science 1995, 269:973-977.
11. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang G,
Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Placen-
tini S, Amaducci L, Chumakov I, Cohen D, Lannfelt L, Fraser PE, Rom-
mens JM, St George-Hyslop PH: Familial Alzheimer's disease in
kindreds with missense mutations in a gene on chromosome
1 related to the Alzheimer's disease type 3 gene.  Nature 1995,
376:775-778.
12. Pericak-Vance MA, Bebout JL, Gaskell PC, Yamaoka LH, Hung W-Y,
Alberts MJ, Walker AP, Bartlett RJ, Haynes CS, Welsh KA, Earl NL,
Heyman A, Clark CM, Roses AD: Linkage studies in familial
Alzheimer's disease: evidence for chromosome 19 linkage.
Am J Hum Genet 1991, 48:1034-1050.
13. Menzel H-J, Kladetzky RG, Asman G: Apolipoprotein E polymor-
phism and coronary artery disease.  Arteriosclerosis 1983,
3:310-315.BMC Medical Genetics 2006, 7:19 http://www.biomedcentral.com/1471-2350/7/19
Page 8 of 9
(page number not for citation purposes)
14. Saunders AM, Strittmatter WJ, Breitner JC, Schmechel D, St George-
Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-
MacLachlan DR, Growden J, Alberts MJ, Hulette C, Crain B, Goldga-
ber D, Roses AD: Association of apolipoprotein E allele 4 with
late-onset familial and sporadic Alzheimer's disease.  Neurol-
ogy 1993, 43:1467-1472.
15. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell
PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose
of apolipoprotein E type 4 allele and the risk of Alzheimer's
disease in late onset families.  Science 1993, 261:921-923.
16. Pericak-Vance MA, Johnson CC, Rimmler JB, Saunders AM, Robinson
LC, D'Hondt EG, Jackson CE, Haines JL: Alzheimer's disease and
apolipoprotein E-4 allele in an Amish population.  Annals of
Neurology 1996, 39:700-704.
17. Pericak-Vance MA, Yamaoka LH, Haynes CS, Speer MC, Haines JL,
Gaskell PC, Hung W-Y, Clark CM, Heyman A, Trofatter J, Eisen-
menger JP, Gilbert JR, Lee JE, Alberts MJ, Dawson DV, Bartlett RJ, Earl
NL, Siddique T, Vance JM, Conneally PM, Roses AD: Genetic link-
age studies in Alzheimer's disease families.  Experimental Neu-
rology 1988, 102:271-279.
18. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK,
Terwedow HA, Menold MM, Conneally PM, Small GW, Vance JM,
Saunders AM, Roses AD, Haines JL: Complete genomic screen in
late-onset familial Alzheimer disease: evidence for a new
locus on chromosome 12.  JAMA 1997, 278:1237-1241.
19. Scott WK, Hauser ER, Schmechel DE, Welsh-Bohmer KA, Small GW,
Roses AD, Saunders AM, Gilbert JR, Vance JM, Haines JL, Pericak-
Vance MA: Ordered-subsets linkage analysis detects novel
Alzheimer disease loci on chromosomes 2q34 and 15q22.  Am
J Hum Genet 2003, 73:1041-1051.
20. Pericak-Vance MA, Bass ML, Yamaoka LH, Gaskell PC, Scott WK,
Terwedow HA, Menold MM, Conneally PM, Small GW, Saunders AM,
Roses AD, Haines JL: Complete genomic screen in late-onset
familial Alzheimer's disease.  Neurobiol Aging 1998, 19:S39-S42.
21. Zubenko GS, Hughes HB, Stiffler JS, Hurtt MR, Kaplan BB: A
genome survey for novel Alzheimer disease risk loci: results
at 10-cM resolution.  Genomics 1998, 50:121-128.
22. Zubenko GS, Stiffler JS, Hughes HB, Hurtt MR, Kaplan BB: Initial
results of a genome survey for novel Alzheimer's disease risk
genes: association with a locus on the X chromosome.  Am J
Med Genet 1998, 81:196-205.
23. Rogaeva E, Premkumar S, Song Y, Sorbi S, Brindle N, Paterson A,
Duara R, Levesque G, Yu G, Nishimura M, Ikeda M, O'Toole C,
Kawarai T, Jorge R, Vilarino D, Bruni AC, Farrer LA, St George-Hys-
lop PH: Evidence for an Alzheimer disease susceptibility locus
on chromosome 12 and for further locus heterogeneity.
JAMA 1998, 280:614-618.
24. Kehoe P, Wavrant-De VF, Crook R, Wu WS, Holmans P, Fenton I,
Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-
Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van
Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ: A full
genome scan for late onset Alzheimer's disease.  Hum Mol
Genet 1999, 8:237-245.
25. Scott WK, Grubber JM, Conneally PM, Small GW, Hulette CM,
Rosenberg CK, Saunders AM, Roses AD, Haines JL, Pericak-Vance
MA: Fine mapping of the chromosome 12 late-onset alzhe-
imer disease locus: potential genetic and phenotypic hetero-
geneity.  Am J Hum Genet 2000, 66:922-932.
26. Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro
L, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott
WK, Conneally PM, Vance JM, Haines JL: Identification of novel
genes in late-onset Alzheimer's disease.  Exp Gerontol 2000,
35:1343-1352.
27. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears
S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall
N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L,
Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM:
Susceptibility locus for Alzheimer's disease on chromosome
10.  Science 2000, 290:2304-2305.
28. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S,
McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE:
Evidence for genetic linkage of Alzheimer's disease to chro-
mosome 10q.  Science 2000, 290:2302-2303.
29. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M,
Adamson J, Ronald J, Blangero J, Hutton M, Younkin SG: Linkage of
plasma Abeta42 to a quantitative locus on chromosome 10
in late-onset Alzheimer's disease pedigrees.  Science 2000,
290:2303-2304.
30. Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R,
Compton D, Marshall H, Meyer D, Shears S, Booth J, Ramic D, Know-
les H, Morris JC, Williams N, Norton N, Abraham R, Kehoe P, Wil-
liams H, Rudrasingham V, Rice F, Giles P, Tunstall N, Jones L,
Lovestone S, Williams J, Owen MJ, Hardy J, Goate A: Full genome
screen for Alzheimer disease: stage II analysis.  Am J Med Genet
2002, 114:235-244.
31. Mayeux R, Lee JH, Romas SN, Mayo D, Santana V, Williamson J,
Ciappa A, Rondon HZ, Estevez P, Lantigua R, Medrano M, Torres M,
Stern Y, Tycko B, Knowles JA: Chromosome-12 mapping of late-
onset Alzheimer disease among Caribbean Hispanics.  Am J
Hum Genet 2002, 70:237-243.
32. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener
H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin
MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett
SS, Doheny KJ, Pugh EW, Tanzi RE: Results of a high-resolution
genome screen of 437 Alzheimer's disease families.  Hum Mol
Genet 2003, 12:23-32.
33. Farrer LA, Bowirrat A, Friedland RP, Waraska K, Korczyn AD, Bald-
win CT: Identification of multiple loci for Alzheimer disease
in a consanguineous Israeli-Arab community.  Hum Mol Genet
2003, 12:415-422.
34. Holmans P, Hamshere M, Hollingworth P, Rice F, Tunstall N, Jones S,
Moore P, DeVrieze FW, Myers A, Crook R, Compton D, Marshall H,
Meyer D, Shears S, Booth J, Ramic D, Williams N, Norton N, Abra-
ham R, Kehoe P, Williams H, Rudrasingham V, O'donovan M, Jones L,
Hardy J, Goate A, Lovestone S, Owen M, Williams J: Genome
screen for loci influencing age at onset and rate of decline in
late onset Alzheimer's disease.  Am J Med Genet B Neuropsychiatr
Genet 2005, 135:24-32.
35. Avramopoulos D, Fallin MD, Bassett SS: Linkage to chromosome
14q in Alzheimer's disease (AD) patients without psychotic
symptoms.  Am J Med Genet B Neuropsychiatr Genet 2005, 132:9-13.
36. Schellenberg GD, D'Souza I, Poorkaj P: The genetics of Alzhe-
imer's disease.  Curr Psychiatry Rep 2000, 2:158-164.
37. Bertram L, Tanzi RE: Alzheimer's disease: one disorder, too
many genes?  Hum Mol Genet 2004, 13(Spec No 1):R135-R141.
38. Jackson CE, Symon WE, Pruden EL, Kaer IM, Mann JD: Consanguin-
ity and blood group distribution in an Amish isolate.  Am J
Hum Genet 1968, 20:522-527.
39. Gingerich HF, Kreider RW: Amish and Amish Mennonite Genealogies
Gordonville, PA: Pequea Publishers; 1986. 
40. Hostetler J: Amish Society 4th edition. Baltimore, MD: Johns hopkins
University Press; 1993. 
41. Kraybill DB: The Riddle of Amish Culture Baltimore, MD: Johns Hopkins
University Press; 2001. 
42. Van Der Walt JM, Scott WK, Slifer S, Gaskell PC, Martin ER, Welsh-
Bohmer K, Creason M, Crunk A, Fuzzell D, McFarland L, Kroner CC,
Jackson CE, Haines JL, Pericak-Vance MA: Maternal lineages and
Alzheimer disease risk in the Old Order Amish.  Hum Genet
2005, 118:115-122.
43. Hahs DW, McCauley JL, Crunk AE, McFarland LL, Gaskell PC, Jiang L,
Slifer SH, Vance JM, Scott WK, Welsh-Bohmer KA, Johnson SR, Jack-
son CE, Pericak-Vance MA, Haines JL: A genome-wide linkage
analysis of dementia in the Amish.  Am J Med Genet B Neuropsy-
chiatr Genet 2006, 141:160-166.
44. Agarwala R, Biesecker LG, Schaffer AA: Anabaptist genealogy
database.  Am J Med Genet C Semin Med Genet 2003, 121:32-37.
45. Sobel E, Lange K: Descent graphs in pedigree analysis: applica-
tions to haplotyping, location scores, and marker-sharing
statistics.  Am J Hum Genet 1996, 58:1323-1337.
46. Abney M, Ober C, McPeek MS: Quantitative-trait homozygosity
and association mapping and empirical genomewide signifi-
cance in large, complex pedigrees: fasting serum-insulin
level in the Hutterites.  Am J Hum Genet 2002, 70:920-934.
47. Bourgain C, Hoffjan S, Nicolae R, Newman D, Steiner L, Walker K,
Reynolds R, Ober C, McPeek MS: Novel case-control test in a
founder population identifies P-selectin as an atopy-suscepti-
bility locus.  Am J Hum Genet 2003, 73:612-626.
48. Bourgain C, Genin E: Complex trait mapping in isolated popu-
lations: Are specific statistical methods required?  Eur J Hum
Genet 2005, 13:698-706.
49. Heath S, Robledo R, Beggs W, Feola G, Parodo C, Rinaldi A, Contu
L, Dana D, Stambolian D, Siniscalco M: A novel approach toPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2006, 7:19 http://www.biomedcentral.com/1471-2350/7/19
Page 9 of 9
(page number not for citation purposes)
search for identity by descent in small samples of patients
and controls from the same mendelian breeding unit: a pilot
study on myopia.  Hum Hered 2001, 52:183-190.
50. Moore JH: The ubiquitous nature of epistasis in determining
susceptibility to common human diseases.  Hum Hered 2003,
56:73-82.
51. Agarwala R, Schaffer AA, Tomlin JF: Towards a complete North
American Anabaptist Genealogy II: analysis of inbreeding.
Hum Biol 2001, 73:533-545.
52. Agarwala R, Biesecker LG, Hopkins KA, Francomano CA, Schaffer
AA: Software for constructing and verifying pedigrees within
large genealogies and an application to the Old Order Amish
of Lancaster County.  Genome Res 1998, 8:211-221.
53. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a prac-
tical method for grading the cognitive state of patients for
the clinician.  Journal of Psychiatric Research 1975, 12:189-198.
54. Mattis S: Mental status examination for organic mental syn-
drome in the elderly patient.  In Geriatric Psychiatry Edited by: Bel-
lak L, Karasu TB. New Your, NY: Grune & Stratton; 1976. 
55. Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test Philadel-
phia, PA: Lea & Febiger; 1976. 
56. Jastak S, Wilkinson GS: Wide Range Achievement Test-Revised Wilming-
ton, Delaware: Jastak Associates; 1984. 
57. Ashley-Koch AE, Shao Y, Rimmler JB, Gaskell PC, Welsh-Bohmer KA,
Jackson CE, Scott WK, Haines JL, Pericak-Vance MA: An autosomal
genomic screen for dementia in an extended Amish family.
Neurosci Lett 2005, 379:199-204.
58. Genome Database   [http://www.gdb.org/]
59. Primer3   [http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi]
60. Vance JM, Othmane KB: Methods of genotyping: Design and
implementation of mapping studies ofr complex human dis-
eases.  In Current Protocols in Human Genetics Edited by: Haines JL,
Pericak-Vance MA. New York: John Wiley & Sons Inc, New York;
1998. 
61. O'Connell JR, Weeks DE: PedCheck: a program for identifica-
tion of genotype incompatibilities in linkage analysis.  Am J
Hum Genet 1998, 63:259-266.
62. Ihaka R, Gentleman R: A Language for Data Analysis and
Graphics.  Journal of Computational and Graphical Statistics 1996,
5:299-314.
63. Mehta CR, Patel NR: Algorithm 643. FEXACT: A Fortran sub-
routine for Fisher's exact test on unordered r*c contingency
tables.  ACM Transactions on Mathematical Software 1986, 12:154-161.
64. Clarkson DB, Fan Y, Joe H: A Remark on Algorithm 643: FEX-
ACT: An Algorithm for Performing Fisher's Exact Test in r
× c Contingency Tables.  ACM Transactions on Mathematical Soft-
ware 1993, 19:484-488.
65. Hiltunen M, Mannermaa A, Thompson D, Easton D, Pirskanen M,
Helisalmi S, Koivisto AM, Lehtovirta M, Ryynanen M, Soininen H:
Genome-wide linkage disequilibrium mapping of late-onset
Alzheimer's disease in Finland.  Neurology 2001, 57:1663-1668.
66. Pola R, Flex A, Gaetani E, Santoliquido A, Serricchio M, Pola P, Bern-
abei R: Intercellular adhesion molecule-1 K469E gene poly-
morphism and Alzheimer's disease.  Neurobiol Aging 2003,
24:385-387.
67. Mattila KM, Hiltunen M, Rinne JO, Mannermaa A, Roytta M, Alafuzoff
I, Laippala P, Soininen H, Lehtimaki T: Absence of association
between an intercellular adhesion molecule 1 gene E469K
polymorphism and Alzheimer's disease in Finnish patients.
Neurosci Lett 2003, 337:61-63.
68. Rodero L, Infante J, Palacio E, Llorca J, Berciano J, Combarros O: Pol-
ymorphism at codon 469 of the intercellular adhesion mole-
cule-1 gene is not associated with sporadic Alzheimer's
disease.  Am J Med Genet B Neuropsychiatr Genet 2004, 126:66-68.
69. Wijsman EM, Daw EW, Yu CE, Payami H, Steinbart EJ, Nochlin D,
Conlon EM, Bird TD, Schellenberg GD: Evidence for a novel late-
onset Alzheimer disease locus on chromosome 19p13.2.  Am
J Hum Genet 2004, 75:398-409.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/7/19/prepub